Last reviewed · How we verify
Sequential therapy for 14 days
Sequential therapy for 14 days refers to a treatment regimen combining multiple therapeutic agents administered in a planned sequence over a two-week period.
At a glance
| Generic name | Sequential therapy for 14 days |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This is a treatment protocol rather than a single drug entity. Sequential therapy typically involves administering different antimicrobial or therapeutic agents in a coordinated sequence to optimize efficacy, reduce resistance development, or manage complex infections. The specific mechanism depends on the individual agents used in the sequence.
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (PHASE3)
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NA)
- Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer (PHASE2)
- Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study (PHASE4)
- A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (PHASE2)
- LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer (PHASE1)
- Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC (PHASE3)
- Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sequential therapy for 14 days CI brief — competitive landscape report
- Sequential therapy for 14 days updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI